2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Kidney Transplantation is Associated with a Significant Survival Benefit among Co-infected HIV+ Candidates

Benefitachieved392dayspost-transplant

Locke JEet.al.Survival benefit ofkidney transplantation inHIV-infected patients. AnnalsofSurgery 2017,265(3):604-608.

Slide37of63FromJELocke,MD,MPHatNewOrleans,LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICAL CONFERENCE, IAS  USA.

Can Increased Risk Associated with HCV Infection be Mitigated among HIV+ Candidates?

YES!



1.AvoidhighdegreesofHLAmismatching 2.Antiviral therapy toeradicateHCV (pre vs.post-transplantreferral?)

Locke JEet.al. Identification ofoptimal donor-recipient combinationsamongHIV-positive kidney transplant recipients. American JournalofTransplantation 2016,16(8):2368-76.

Slide38of63FromJELocke,MD,MPHatNewOrleans,LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICAL CONFERENCE, IAS  USA.

ARS Question 2: What is the optimal timing for HCV treatment? A. Always pre-transplant B. Depends only on fibrosis stage C. Depends only on waiting time D. Depends on both fibrosis stage and waiting time

Slide39of63FromJELocke,MD,MPHatNewOrleans,LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICAL CONFERENCE, IAS  USA.